Seoul – South Korea is in talks to purchase 40 million doses of a coronavirus vaccine developed by Novavax, its local manufacturer SK Bioscience said Wednesday.
The deal, if agreed, will boost supply of COVID-19 vaccines in the country to 146 million doses, more than enough for its 52 million residents, and comes as it prepares to start mass inoculations in February.
SK bioscience, which also manufactures AstraZeneca’s COVID-19 vaccine, is working on a technology transfer deal with Novavax which will allow it to produce and sell vaccines on its own, the drugmaker arm of SK Chemicals said.
A deal with the South Korean government could be its first direct supply deal.
South Korea’s President Moon Jae-in visited SK’s worksite Wednesday and said the agreement between Novavax and SK bioscience raised the possibility of securing additional doses of vaccines.
The country has already secured 106 million doses from global vaccine supply facility COVAX and Western drugmakers including Pfizer, Moderna, AstraZeneca and Johnson & Johnson.
Moon’s visit comes as his administration faces criticism for not taking the necessary steps to achieve its goal of reaching herd immunity to the coronavirus through mass vaccinations by November.
The government had laid out a timeline that calls for vaccinations of key individuals to begin in February, with 32 million to 36 million people vaccinated by September.
South Korea reported 404 new coronavirus cases as of Tuesday, bringing the country’s tally to 73,518 cases, with 1,300 deaths.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.